Aileron Therapeutics Inc (NASDAQ:ALRN) major shareholder Bioventures Ltd Novartis sold 190,338 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $2.06, for a total transaction of $392,096.28. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
ALRN traded down $0.02 on Friday, reaching $1.90. The company’s stock had a trading volume of 209,700 shares, compared to its average volume of 353,694. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $28.17 million, a price-to-earnings ratio of -1.07 and a beta of 3.18. Aileron Therapeutics Inc has a fifty-two week low of $0.52 and a fifty-two week high of $9.50.
A number of brokerages recently issued reports on ALRN. Zacks Investment Research downgraded Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 20th. HC Wainwright began coverage on Aileron Therapeutics in a report on Monday. They issued a “buy” rating and a $7.00 price target for the company. Finally, ValuEngine downgraded Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 24th.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc boosted its holdings in shares of Aileron Therapeutics by 8.0% in the third quarter. Vanguard Group Inc now owns 96,415 shares of the company’s stock valued at $265,000 after acquiring an additional 7,109 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Aileron Therapeutics in the third quarter valued at approximately $137,000. Bridgeway Capital Management Inc. boosted its holdings in shares of Aileron Therapeutics by 78.6% in the third quarter. Bridgeway Capital Management Inc. now owns 113,600 shares of the company’s stock valued at $312,000 after acquiring an additional 50,000 shares during the period. Finally, Parkwood LLC acquired a new stake in shares of Aileron Therapeutics in the third quarter valued at approximately $149,000. 9.16% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Bioventures Ltd Novartis Sells 190,338 Shares of Aileron Therapeutics Inc (ALRN) Stock” was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.thestockobserver.com/2019/03/15/bioventures-ltd-novartis-sells-190338-shares-of-aileron-therapeutics-inc-alrn-stock.html.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Featured Story: Certificate of Deposit (CD)
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.